Timing and specificity of the cognitive changes induced by interleukin-2 and interferon-α treatments in cancer patients

Psychosomatic Medicine

Volumn 63, Issue 3, 2001, Pages 376-386

  Capuron, Lucile ^a,b   Ravaud, Alain ^c   Dantzer, Robert ^a  

^a INSTITUT FRANÇOIS MAGENDIE   (France)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c INSTITUT BERGONIÉ   (France)

Author keywords

Cancer immunotherapy; Cognitive performance; Interferon ; Interleukin 2; Neuropsychology; Side effects

Indexed keywords

ALPHA INTERFERON; INTERLEUKIN 2;

ADULT; ARTICLE; CANCER; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HUMAN; LATENT PERIOD; MALE; NEUROPSYCHOLOGY; PERFORMANCE; PLANNING; PRIORITY JOURNAL; REACTION TIME; TASK PERFORMANCE; TREATMENT PLANNING; WORKING MEMORY;

EID: 0034999297     PISSN: 00333174     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006842-200105000-00007     Document Type: Article

References (52)

1. Dantzer R. How do cytokines say hello to the brain? Neural versus humoral mediation. Eur Cyt Netw 1994;5:271-3.
2. Kluger MJ. Fever: role of pyrogens and cryogens. Physiol Rev 1991;71:93-127.
3. Besedovsky HO, Del Rey AE, Sorkin E. Immune-neuroendocrine interactions. J Immunol 1985;135(Suppl 2):750S-754S.
4. Dantzer R, Wollman EE, Yirmiya R. Cytokines, stress and depression. New York: Kluwer Academic/Plenum; 1999.
5. Bluthé RM, Beaudu C, Kelley KW, Dantzer R. Differential effects of IL-1ra on sickness behavior and weight loss induced by IL-1 in rats. Brain Res 1995;677:171-6.
6. Yirmiya R. Endotoxin produces a depressive-like episode in rats. Brain Res 1996;711:163-74.
7. Connor T, Song C, Leonard BE, Merali Z, Anisman H. An assessment of the effects of central interleukin-1β, -2, -6 and tumor necrosis factor-α administration on some behavioural, neuro-chemical, endocrine, and immune parameters in the rat. Neuroscience 1998;84:923-33.
8. Smith A, Tyrrell D, Coyle K, Willman JS. Selective effects of minor illnesses on human performance. Br J Psychol 1987;78: 183-8.
9. Smith A, Tyrrell D, Coyle K, Higgins P. Effects of interferon-alpha on performance in man: a preliminary report. Psychopharmacology 1988;96:414-6.
10. Capuron L, Lamarque D, Dantzer R, Goodall G. Attentional and mnemonic deficits associated with infectious disease in humans. Psychol Med 1999;29:291-7.
11. Anisman H, Merali Z. Anhedonic and anxiogenic effects of cytokine exposure. In: Dantzer R, Wollman EE, Yirmiya R, editors. Cytokines, stress and depression. New York: Kluwer Academic/Plenum; 1999. p. 199-233.
12. Aubert A, Vega C, Dantzer R, Goodall G. Pyrogens specifically disrupt the acquisition of a task involving cognitive processing in the rat. Brain Behav Immun 1995;9:129-48.
13. Gibertini M, Newton C, Friedman H, Klein TW. Spatial learning impairment in mice infected with Legionella pneumophila or administered exogenous interleukin-1β. Brain Behav Immun 1995;9:113-28.
14. Denicoff KD, Rubinow DR, Papa MZ, Simpson C, Seipp CA, Lotze MT, Chang AE, Rosenstein D, Rosenberg SA. The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells. Ann Intern Med 1987;107:293-300.
15. Pavol MA, Meyers CA, Rexer JL, Valentine AD, Mattis PJ, Talpaz M. Pattern of the neurobehavioral deficits associated with interferon-alfa therapy for leukemia. Neurology 1995;45:947-950.
16. Meyers CA. Mood and cognitive disorders in cancer patients receiving cytokine therapy. In: Dantzer R, Wollman EE, Yirmiya R, editors. Cytokine, stress and depression. New York: Kluwer Academic/Plenum; 1999. p. 75-81.
17. Walker LG, Wesnes KP, Keys SD, Walker MB, Lolley J, Eremin O. The cognitive effects of recombinant interleukin-2 (rIL-2) therapy: a controlled clinical trial using computerised assessments. Eur J Cancer 1996;32A:2275-83.
18. Walker LG, Walker MB, Heys SD, Lolley J, Wesnes K, Eremin O. The psychological and psychiatric effects of rIL-2 therapy: a controlled clinical trial. Psychooncology 1997;6:290-301.
19. Atzpodien J, Kirchner H. The out-patient use of recombinant interleukin-2 and interferon-alfa-2b in advanced malignancies. Eur J Cancer 1991;27(Suppl 4):S88-91.
20. Capuron L, Ravaud A, Dantzer R. Early depressive symptoms in cancer patients receiving interleukin-2 and interferon-alpha-26 therapy. J Clin Oncol 2000;18:2143-51.
21. Robbins TW, James M, Owen AM, Sahakian BJ, McInnes L, Rabbitt PM. Cambridge Neuropsychological Test Automated Battery (CANTAB): a factor analytic study of a large sample of normal elderly volunteers. Dementia 1994;5:266-81.
22. Robbins TW, James M, Owen AM, Sahakian BJ, Lawrence AD, Mclnnes L, Rabbitt PM. A study of performance on tests from the CANTAB battery sensitive to frontal lobe dysfunction in a large sample of normal volunteers: implications for theories of executive functioning and cognitive aging. J Int Neuropsychol Soc 1998;4:474-90.
23. Sleijfer DT, Janssen RA, Buter J, De Vries EG, Willemse PH, Mulder NH. Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an out-patient basis. J Clin Oncol 1992;10:1119-23.
24. Négrier S, Ravaud A, Delva R, Chevreau C, Douillard JY, Fargeot P, Drevon M, Gomez F. Combination of cytokines in metastatic renal cell carcinoma: is the subcutaneous route less active than the intravenous route? [abstract]. Proc Am Soc Clin Oncol 1999; 18:331A.
25. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996;14:7-17.
26. Fray PJ, Robbins TW, Sahakian BJ. Neuropsychiatric applications of CANTAB. Int J Geriatr Psychiatry 1996;11:329-36.
27. Robbins TW, Sahakian BJ. Computer methods of assessment of cognitive function. In: Copeland JRM, Abou-Saleh MT, Blazer DG, editors. Principles and practice of geriatric psychiatry. Chichester (UK): John Wiley & Sons: 1994. p. 205-9.
28. Owen AM, Sahakian BJ. Semple J, Polkey CE, Robbins TW. Visuo-spatial short-term recognition memory and learning after temporal lobe excisions, frontal lobe excisions or amygdalo-hippocampectomy in man. Neuropsychologia 1995;33:1-24.
29. Robbins TW. Dissociating executive functions of the prefrontal cortex. Philos Trans R Soc Lond B Biol Sci 1996;351:1463-71.
30. Owen AM, James M, Leigh PN, Summers BA, Maesden CD, Quinn NP, Lange KW, Robbins TW. Fronto-striatal cognitive deficits at different stages of Parkinson disease. Brain 1992;115: 1727-51.
31. Owen AM, Downes JJ, Sahakian BJ, Polkey CE, Robbins TW. Planning and spatial working memory following frontal lobe lesions in man. Neuropsychologia 1990;28:1021-34.
32. Owen AM, Doyon J, Petrides M, Evans AC. Planning and spatial working memory: a positron emission tomography study in humans. Eur J Neurosci 1996;8:353-64.
33. Baker SC, Rogers RD, Owen AM, Frith CD, Dolan RJ, Frakowiak RSJ, Robbins TW. Neural systems engaged by planning: a PET study of the Tower of London task. Neuropsychologia 1996;34: 515-26.
34. World Health Organization. WHO handbook for reporting results of cancer treatment. Geneva: World Health Organization; 1979. WHO offset publication no. 48.
35. Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeod CM, editor. Evaluation of chemotherapeutic agents in cancer. New York: Columbia University Press; 1949. p. 191-205.
36. Montgomery SA, Asberg A. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-9.
37. Monk MM, Leng VC, Folkard S, Weitzman ED. Circadian rhythms in subjective alertness and core body temperature. Chronobiologia 1983;10:49-55.
38. Lowe C, Rabbitt P. Test/re-test reliability of the CANTAB and ISPOCD neuropsychological batteries: theoretical and practical issues. Neuropsychologia 1998;36:915-23.
39. Pearson K. On a criterion that a given system of deviations from the probable in the case of a correlated system of variables is such that it can reasonably be supposed to have arisen in random sampling. Philos Magazine 1900;50:157-75.
40. Pace A, Pietrangeli A, Bove L, Rosselli M, Lopez M, Jandolo B. Neurotoxicity of antitumoral IL-2: evoked cognitive potentials and brain mapping. Ital J Neurol Sci 1994;15:341-6.
41. Caraceni A, Martini C, Belli F, Mascheroni L, Rivoltini L, Arienti F, Cascinelli N. Neuropsychological and neurophysiological assessment of the central effects of interleukin-2 administration. Eur J Cancer 1993;29A:1266-9.
42. Karp B, Yang JC, Khorsand M, Wood R, Merigan TC. Multiple cerebral lesions complicating therapy with interleukin-2. Neurology 1996;47:417-24.
43. Drevets WC, Videen TO, Price JL, Preskorn SH, Carmichael ST, Raichle ME. A functional anatomical study of unipolar depression. J Neurosci 1992;12:3628-41.
44. Araujo DM, Lapchak PA, Collier B, Quirion R. Localization of interleukin-2 immunoreactivity and interleukin-2 receptors in the rat brain: interaction with the cholinergic system. Brain Res 1989;498:257-266.
45. Lapchak PA, Araujo DM. Quirion R, Beaudet A. Immunoautoradiographic localization of interleukin-2-like immunoreactivity and interleukin-2 receptors (Tac antigen-like-immunoreactivity) in the rat brain. Neuroscience 1991;44:173-84.
46. Hanisch UK, Quirion R. Interleukin-2 as a neuroregulatory cytokine. Brain Res Rev 1995;21:246-84.
47. Hanisch UK, Seto D, Quirion R. Modulation of hippocampal acetylcholine release: a potent central action of interleukin-2. J Neurosci 1993;13:3368-74.
48. Dantzer R, Aubert A, Bluthe RM, Gheusi G, Cremona S, Laye S, Konsman JP, Parnet P, Kelley KW. Mechanisms of the behavioural effects of cytokines. In: Dantzer R, Wollman EE, Yirmiya R, editors. Cytokine, stress and depression. New York: Kluwer Academic/Plenum; 1999. p. 83-105.
49. Hull M, Fiebich BL, Lieb K, Strauss S, Berger SS, Volk B, Bauer J. Interleukin-6-associated inflammatory processes in Alzheimer's disease: new therapeutic options. Neurobiol Aging 1996; 17:795-800.
50. Rogers J, Webster S, Lue LF, Brachova L, Civin WH, Emmerling M, Shivers B, Walker D, McGeer P. Inflammation and Alzheimer's disease pathogenesis. Neurobiol Aging 1996;17:681-6.
51. Dunn AL, Crnic LS. Repeated injections of interferon-alpha A/D in Balb/c mice: behavioral effects. Brain Behav Immun 1993;7: 104-11.
52. Shuto H, Kataoka Y, Horikawa T, Fujihara N, Oishi R. Repeated interferon-alpha administration inhibits dopaminergic neural activity in the mouse brain. Brain Res 1997;747: 348-51.